Multidrug resistance and prodrug activation for cancer gene therapy of breast cancer

Takuma Fujii, S. Q. Fu, L. H. Yin, T. Nanakorn, Felix Garcia Sanchez, Matt Cooperberg, David Guo, Tao Wang, D. Lin, Giuseppe Pizzorno, Albert Deisseroth

研究成果: Article

抜粋

Current approaches to the treatment of cancer (radiation and chemotherapy) are limited by the toxicity to normal tissues and the sensitivity of tumor cells to these treatments. The use of gene delivery vector systems for the introduction of genetic elements into normal and neoplastic tissues which code for proteins that protect the normal chemotherapy-sensitive tissues and sensitize the tumor cells to radiation and chemotherapy, may contribute to an overall improvement in the outcome of cancer treatment programs. This chapter will review the clinical trials either completed or about to be initiated which are designed to accomplish these goals.

元の言語English
ページ(範囲)210-212
ページ数3
ジャーナルBreast Cancer
4
発行部数4
DOI
出版物ステータスPublished - 01-12-1997
外部発表Yes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

フィンガープリント Multidrug resistance and prodrug activation for cancer gene therapy of breast cancer' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Fujii, T., Fu, S. Q., Yin, L. H., Nanakorn, T., Sanchez, F. G., Cooperberg, M., Guo, D., Wang, T., Lin, D., Pizzorno, G., & Deisseroth, A. (1997). Multidrug resistance and prodrug activation for cancer gene therapy of breast cancer. Breast Cancer, 4(4), 210-212. https://doi.org/10.1007/BF02966508